April 18, 2007 - Masimo Corp. filed with the Securities and Exchange Commission for an initial public offering of up to $150 million in common stock. The Irvine, CA-based medical technology company makes noninvasive patient monitoring products.

The company didn't disclose how many shares will be offered, nor did it provide an estimated price range for the offering.

The company said it expects to use about $15 million to $20 million of the net proceeds from this offering in capital expenditures and deferred cost of sales, primarily representing the placement of equipment under long-term sensor purchase contracts, and about $7.5 million in miscellaneous capital purchases.

The company said it intends to use the remainder net proceeds for ongoing research and development, sales and marketing activities and increased costs associated with becoming a public company.

Piper Jaffray, Deutsche Bank Securities, Cowen and Co. and Thomas Weisel Partners LLC are listed as underwriters for the offering.

The company said it plans to list its stock on the Nasdaq Global Market, under the symbol of MASI.

For the year 2006, the company's net income increased to $181.6 million from 2005's $33.4 million. Its 2006 revenue more than doubled to $224 million from $108 million in 2005, according to the company's prospectus.


Related Content

News | Image Guided Radiation Therapy (IGRT)

June 7, 2022 — Two-year results from the Dysphagia-Aspiration Related Structures (DARS) trial, which is funded by Cancer ...

Time June 07, 2022
arrow
News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Radiation Oncology

August 27, 2021 — For decades, the National Comprehensive Cancer Network (NCCN) recommended forgoing post-lumpectomy ...

Time August 27, 2021
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Image Guided Radiation Therapy (IGRT)

February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive ...

Time February 11, 2020
arrow
News | Radiology Imaging

December 12, 2019 — Philips and the Regional Medical Center (RMC) announced a strategic 5-year partnership agreement ...

Time December 12, 2019
arrow
News | Radiation Therapy

October 22, 2019 — The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) ...

Time October 22, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

Time October 08, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.

Time September 16, 2019
arrow
Subscribe Now